2010
DOI: 10.1002/ijc.25042
|View full text |Cite
|
Sign up to set email alerts
|

Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis

Abstract: Recent evidence highlights the potential prognostic and predictive value of BRAF and K‐RAS gene alterations in patients with colorectal cancer. However, a comprehensive evaluation of BRAF and K‐RAS mutations and their specific clinicopathological features, histomorphological presentation and effect on protein expression have not been systematically analyzed. The aim of this study was to characterize the clinicopathological, histomorphological and protein expression profiles of BRAF‐ and K‐RAS‐mutated colorecta… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

12
109
2
13

Year Published

2010
2010
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 153 publications
(136 citation statements)
references
References 38 publications
12
109
2
13
Order By: Relevance
“…Despite its predictive role, KRAS mutation has not been shown as a prognostic marker in many large-scale studies (Finkelstein et al, 1993;Samowitz et al, 2000;Gnanasampanthan et al, 2001;Ince et al, 2005;Barault et al, 2008b;Zlobec et al, 2009;Ogino et al, 2009a;Ogino et al, 2009b;Roth et al, 2010), except for one large study (Barault et al, 2008a). Overall evidence supports a null prognostic role of KRAS mutation even if a previous meta-analyses (Andreyev et al, 1998;Andreyev et al, 2001) led to wrong conclusions likely due to the well-known positive publication bias.…”
Section: Kras Somatic Mutationsmentioning
confidence: 98%
See 1 more Smart Citation
“…Despite its predictive role, KRAS mutation has not been shown as a prognostic marker in many large-scale studies (Finkelstein et al, 1993;Samowitz et al, 2000;Gnanasampanthan et al, 2001;Ince et al, 2005;Barault et al, 2008b;Zlobec et al, 2009;Ogino et al, 2009a;Ogino et al, 2009b;Roth et al, 2010), except for one large study (Barault et al, 2008a). Overall evidence supports a null prognostic role of KRAS mutation even if a previous meta-analyses (Andreyev et al, 1998;Andreyev et al, 2001) led to wrong conclusions likely due to the well-known positive publication bias.…”
Section: Kras Somatic Mutationsmentioning
confidence: 98%
“…In addition to its predictive role, BRAF mutation is a prognostic marker in colon cancer as shown in most of the large series This prognostic impact is mainly due to the impact of BRAF mutations in the subgroup of microsatellite stable tumours (Samowitz et al, 2005b;French et al, 2008;Kim et al, 2009;Zlobec et al, 2009;Ogino et al, 2009b;Roth et al, 2010), although it was not the case in one large series (Barault et al, 2008a).…”
Section: Kras Somatic Mutationsmentioning
confidence: 99%
“…Often, results were not statistically significant, possibly due to lack of power. Eighteen studies were included in an analysis on KRAS status in MC and NMC and KRAS mutations were found in MC more frequently (RR 1.27, 95% CI 1.14-1.41; Figure 1) [6,33,[47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62].…”
Section: Krasmentioning
confidence: 99%
“…BRAF is the downstream effector of KRAS and is also involved in the RAS/RAF/MAPK pathway. In various studies, mutational BRAF was found in 0-46% of MC patients, whereas 6-25% of NMC tumours displayed mutated BRAF (RR 2.04, 95% CI 1.67-2.51; Figure 2) [6,33,42,48,50,[56][57][58][59]63]. BRAF mutations lead to constitutive activation of the RAS/RAF/MAPK signalling pathway [64].…”
Section: Brafmentioning
confidence: 99%
“…Mutations in any of these codons lead to a constitutively activated RAS protein. [3][4][5][6] The relationship between K-ras mutations and the clinical/ morphological parameters of CRC has been extensively investigated. Some epidemiological studies show a prevalence of K-ras codon 12 mutations over mutations in codon 13 in CRC tumours.…”
mentioning
confidence: 99%